Evidence map›Paper›PMID 42213373›Full record

ArticleMolecular diversity2026

Naphthalene-based hydroxamate HDAC inhibitors with anti-breast tumor activity.

Hui Song, Feng-Chao Wang, Wan-Dong Liu, Quan-Hao Wei, Feifei Yang, Peipei Shan, Hua Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Song *School of Biological Science and Technology, University of Jinan, Jinan, 250022, China.
Feng-Chao Wang *School of Biological Science and Technology, University of Jinan, Jinan, 250022, China.
Wan-Dong LiuSchool of Biological Science and Technology, University of Jinan, Jinan, 250022, China.
Quan-Hao WeiSchool of Biological Science and Technology, University of Jinan, Jinan, 250022, China.
Feifei YangSchool of Biological Science and Technology, University of Jinan, Jinan, 250022, China. bio_yangff@ujn.edu.cn.
Peipei ShanInstitute of Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao, 266021, China. shanpeipei@qdu.edu.cn.
Hua ZhangSchool of Biological Science and Technology, University of Jinan, Jinan, 250022, China. bio_zhangh@ujn.edu.cn.

Funding

National Natural Science Foundation of China 82073729, 82273819Natural Science Foundation of Shandong Province ZR2025MS1335
6 · The paper itself

Abstract

Histone deacetylases (HDACs) are attractive therapeutic targets due to their established role in tumorigenesis. In this study, a series of naphthalene-based hydroxamate derivatives were designed and synthesized as novel HDAC inhibitors. Among them, compound 6e showed excellent inhibitory activities against HDAC1 and 4T1 cancer cell line, and it also increased the levels of acetylated histones H3 and H4. Moreover, 6e induced significant cell apoptosis and cycle arrest. Importantly, 6e exhibited significant antitumor activity in the 4T1 orthotopic autograft mouse model. Collectively, these results identify the naphthalene-hydroxamate scaffold as a promising template for the development of novel HDAC-targeted anticancer agents.

Indexed as

Antineoplastic AgentsBreast NeoplasmsHistone Deacetylase InhibitorsHydroxamic AcidsNaphthalenesAcetylationAnimalsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationFemaleHistonesHumansMiceStructure-Activity RelationshipAntineoplastic AgentsHistone Deacetylase InhibitorsHistonesHydroxamic AcidsnaphthaleneNaphthalenesAnticancerHistone deacetylase inhibitorHydroxamateNaphthaleneStructural modification

Identifiers

PMID42213373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.